Pharmaceutical Executive

Pharmaceutical Executive Podcast
  • 5.0(1개의 평가)
  • 생명 과학
  • 매일 업데이트

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

  1. Pharmaceutical Executive Daily: FDA Approves Wegovy Pill

    2025. 12. 23.

    Pharmaceutical Executive Daily: FDA Approves Wegovy Pill

    In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears Roche’s Lunsumio Velo for adults with relapsed or refractory follicular lymphoma, and Alnylam announces a $250 million investment in a new Massachusetts manufacturing facility.

    2분
  2. Pharmaceutical Executive Daily: Nine New Additions to TrumpRx

    2025. 12. 22.

    Pharmaceutical Executive Daily: Nine New Additions to TrumpRx

    In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, AstraZeneca reaches a $2 billion licensing agreement with Jacobio Pharma for a pan-KRAS inhibitor, and BioMarin enters a definitive $4.8 billion agreement to acquire Amicus Therapeutics.

    2분
  3. Scaling Sustainability: A Big Pharma Formula

    2025. 12. 22.

    Scaling Sustainability: A Big Pharma Formula

    In this enlightening conversation with Pharm Exec, Jim Greffet, VP of sustainability at Eli Lilly, unpacks how environmental, social, and governance (ESG) goals are shaping the organization's next phase of growth—particularly as demand surges for its GLP-1 products Zepbound and Mounjaro. From access and affordability to supply chain expansion and climate commitments, Greffet discusses the importance of establishing ESG as a core business driver for manufacturers—and key component to long-term operational strategy and thinking.

    17분
  4. Pharmaceutical Executive Daily: US Senate Passes Biosecure Act

    2025. 12. 19.

    Pharmaceutical Executive Daily: US Senate Passes Biosecure Act

    In today’s Pharmaceutical Executive Daily, Eli Lilly announces positive topline Phase III data for its oral GLP-1 candidate orforglipron, the U.S. Senate passes the Biosecure Act with implications for biopharma supply chains, and industry experts examine how rebate consultants are shaping biosimilar adoption.

    2분
  5. Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release

    2025. 12. 18.

    Pharmaceutical Executive Daily: Pfizer's Stock Drops Following 2026 Revenue Projections Release

    In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House Republicans moves to force a vote on extending ACA tax credits, and new collaboration and merger activity highlights continued dealmaking momentum across biopharma.

    2분
  6. Pharmaceutical Executive Daily: FDA's Approval of Lerochol

    2025. 12. 17.

    Pharmaceutical Executive Daily: FDA's Approval of Lerochol

    In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals spanning Alzheimer’s disease and B-cell depletion, and the agency issues a national priority voucher tied to Tecvayli in multiple myeloma.

    2분
  7. Pharmaceutical Executive Daily: TrumpRx's Critical Blind Spot

    2025. 12. 16.

    Pharmaceutical Executive Daily: TrumpRx's Critical Blind Spot

    In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a national priority voucher tied to Tecvayli in multiple myeloma, and Sobi announces a $1.5 billion agreement to acquire a gout therapy.

    2분
  8. Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results

    2025. 12. 15.

    Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results

    In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and new analysis explores whether pharmaceutical manufacturing is truly moving back onshore.

    2분
모두 보기(260개)

소개

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

정보

  • 제작진
    Pharmaceutical Executive Podcast
  • 방송 연도
    2018년 - 2025년
  • 에피소드
    260
  • 등급
    전체 연령 사용가
  • 웹사이트 보기
    Pharmaceutical Executive

좋아할 만한 다른 항목